[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Baylor Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":622},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,42,67,105,127,149,177,197,219,242,263,282,309,330,357,377,406,435,454,482,511,535,560,578,601],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100642573","scale-up-evaluation-trial-of-the-diabetes-prevention-program-to-improve-obesity-and-cardiometabolic-health-after-traumatic-brain-injury-100642573",false,"NCT07648901","Scale-Up Evaluation Trial of the Diabetes Prevention Program to Improve Obesity and Cardiometabolic Health After Traumatic Brain Injury","GLB Scale-Up","Inclusion Criteria:\n\n* 18-80 years of age\n\n  -≥6 months post-TBI\n* Moderate to severe TBI at time of injury\n* BMI ≥25 kg\u002Fm2\n* Able to communicate in English\n\nExclusion Criteria:\n\n* Contraindications to physical activity\n* Low cognitive function\n* Residing in hospital, acute rehab, SNF\n* Self-Reported Pregnancy\n* Pre-existing diagnosis of an eating disorder\n* Former DPP-GLB Participants (less than 6months since participation ended)","ALL","18 Years","80 Years",{"count":21,"type":22},70,"ESTIMATED","OBSERVATIONAL","The Investigators have proposed targeted efforts to address the feasibility, effectiveness, fidelity, and evaluation of the GLB-TBI Evidence Based Intervention (EBI) in a real world setting at a CDC-recognized site",[26,27,28],"Traumatic Brain Injury","Brain Injuries, Traumatic","Brain Injury, Chronic","NOT_YET_RECRUITING","2026-06-15",{"date":32,"type":33},"2026-06-16","ACTUAL",{"date":35,"type":22},"2026-08-15",{"date":37,"type":22},"2028-08-30",{"name":39,"class":40},"Baylor Research Institute","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100600365","calm-study-cardiomems-assisted-lvad-management-100600365","NCT07096544","CALM Study: Cardiomems Assisted Lvad Management","CALM","Inclusion Criteria:\n\n* Age 21-85\n* Status post HeartMate III Left Ventricular Assist Device Implantation\n* Normally functioning left ventricular assist device as determined by device parameters\n* Stable and ready to be discharged home\n* 18 years of age or older at the time of left ventricular device implantation\n* The patient provides written informed consent before starting any component of this clinical investigation\n\nExclusion Criteria:\n\n* Current\u002Fongoing fevers or constitutional symptoms\n* Bilirubin greater than 2.5µmol\u002FL, shock liver, or biopsy-proven liver cirrhosis\n* Requiring dialysis or declared end stage renal disease\n* Inability to complete written informed consent or a quality-of-life questionnaire\n* Known active malignancy\n* History of recurrent (\\> 1) pulmonary embolism or deep vein thrombosis\n* Unable to tolerate a right heart catheterization\n* Major cardiovascular event (e.g., myocardial infarction, stroke) within 2 months of CardioMEMS implant\n* Glomerular Filtration Rate (GFR) \\\u003C25 ml\u002Fmin who are non-responsive to diuretic therapy\n* Patients likely to undergo heart transplantation within 6 months of Screening Visit\n* Congenital heart disease or mechanical right heart valve(s)\n* Known coagulation disorders\n* Hypersensitivity or allergy to aspirin, and\u002For clopidogrel\n* Pregnant or considering pregnancy\n* Required RV assist device and has severe right heart failure post LVAD implantation","21 Years","85 Years",{"count":5,"type":22},"INTERVENTIONAL",[54],"NA","This prospective, open label, randomized, single-center pilot clinical trial will determine if the rate of heart failure related (HFR) hospitalizations is less in LVAD patients whose PAP is monitored with the CardioMEMS device vs the control patients receiving standard of care treatment.",[57],"Heart Failure","RECRUITING","2026-06-01",{"date":61,"type":33},"2026-06-03",{"date":63,"type":33},"2026-05-08",{"date":65,"type":22},"2027-09-01",{"name":39,"class":40},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":52,"phases":76,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100640562","randomized-ehr-based-prescribing-to-improve-disease-modifying-therapies-for-cardio-kidney-metabolic-care-rapid-ckm-100640562","NCT07605390","RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)","RAPID-CKM: RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care.","Inclusion Criteria\n\n* Adults aged ≥18 years\n* Diagnosis of type 2 diabetes mellitus\n* Receiving outpatient care within Baylor Scott \\& White Health\n* At least 1 outpatient encounter within the preceding 12 months\n* Confirmed albuminuria (UACR \\>30 mg\u002Fg)\n* Eligible for one or more guideline-directed CKM therapies based on - prespecified clinical criteria and EHR review\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Contraindication or documented intolerance to all eligible guideline-directed CKM therapies\n* Advanced kidney dysfunction below recommended initiation thresholds for SGLT2i or finerenone\n* Hyperkalemia or elevated baseline serum potassium precluding safe therapy initiation\n* Contraindicated drug interactions (e.g., strong CYP3A inhibitors with finerenone)\n* Other guideline- or labeling-based contraindications to therapy initiation",{"count":75,"type":22},600,[54],"The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes and confirmed albuminuria.\n\nThe main question it aims to answer is:\n\n• Does an Epic clinician notification improve initiation of guideline-directed CKM therapies compared with usual care?\n\nResearchers will compare an Epic in-basket clinician notification strategy with usual care.\n\nIn the intervention arm, the treating clinician will receive an Epic notification identifying confirmed albuminuria and potential eligibility for guideline-directed CKM therapies using existing electronic health record (EHR) data. Participants in the usual care arm will receive standard clinical care without notification.",[79,80],"Chronic Kidney Disease","Type 2 Diabetes",[82,83,84,85,86,87,88,89,90,91,92,93,94,95,80,79],"Cardio-Kidney-Metabolic Syndrome","Albuminuria","Urine Albumin-to-Creatinine Ratio","Guideline-Directed Medical Therapy","Electronic Health Record","Epic","Implementation Science","Pragmatic Trial","Renin-Angiotensin System Inhibitors","Sodium-Glucose Cotransporter-2 Inhibitors","Glucagon-Like Peptide-1 Receptor Agonists","Non-steroidal Mineralocorticoid Receptor Antagonists","Finerenone","CKM Care","2026-05-19",{"date":98,"type":33},"2026-05-26",{"date":100,"type":22},"2026-08",{"date":102,"type":22},"2028-01",{"name":39,"class":40},2,{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":52,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":41},"100639746","intraoperative-co-carbon-dioxide-100639746","NCT07592468","Intraoperative CO₂ (Carbon Dioxide)","Intraoperative Fractionated CO₂ Laser Treatment of Wound Edges During Mohs Micrographic Surgery","Inclusion Criteria:\n\n* Adults aged 18-89 years\n* Diagnosis of cutaneous malignancy treated with MMS\n* Surgical defect suitable for primary linear or flap closure with adequate length to permit split-scar design\n* Ability to understand and provide informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Inability to provide informed consent\n* Non-English speaking patients\n* History of abnormal wound healing (e.g., keloid disorder)\n* Active infection at the surgical site\n* Immunosuppression felt to significantly impair wound healing\n* Use of isotretinoin within the past 6 months\n* Prior radiation therapy to the surgical site\n* Patients belonging to vulnerable populations including prisoners, children, or individuals unable to consent","89 Years",{"count":114,"type":22},50,[54],"To evaluate whether intraoperative fractionated CO₂ laser treatment of surgical wound edges improves postoperative scar appearance compared with untreated wound edges following Mohs micrographic surgery (MMS).",[118],"Wound Edges","2026-05-18",{"date":121,"type":33},"2026-05-20",{"date":123,"type":22},"2026-05",{"date":125,"type":22},"2027-12",{"name":39,"class":40},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":52,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":148,"locationsCount":41},"100639042","phase-4-skin-subs-vs-secondary-intention-100639042","NCT07587749","Skin Subs vs Secondary Intention","Skin Substitutes Versus Secondary Intention Healing After Mohs Micrographic Surgery","Inclusion Criteria:\n\n* Adults 18 and older undergoing Mohs micrographic surgery\n* Wounds deemed clinically appropriate for secondary intention healing\n* Ability to adhere to daily wound care and follow-up visits\n* Willingness to consent to standardized medical photography\n\nExclusion Criteria:\n\n* Wounds requiring flap or graft reconstruction for structural\u002Ffunctional reasons\n* Active wound infection at time of reconstruction\n* Known allergy to any component of the skin substitute\n* Severe immunosuppression in which either approach may pose undue risk",{"count":114,"type":22},[136],"PHASE4","The purpose of this study is to compare two ways of caring for wounds after Mohs micrographic surgery (MMS) for skin cancer using skin substitutes and secondary intention healing, to determine which option leads to better healing after Mohs surgery.",[139,140,141],"Skin Substitutes","Secondary Intention Healing","Skin Cancer Healing","2026-05-11",{"date":144,"type":33},"2026-05-14",{"date":146,"type":22},"2026-06",{"date":125,"type":22},{"name":39,"class":40},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":52,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":41},"100635068","phase-4-rapid-and-simultaneous-initiation-of-four-guideline-directed-ckd-therapies-rapid-ckd-100635068","NCT07547878","Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)","A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD","RAPID-CKD","Inclusion Criteria:\n\n* Patients aged 18-84 years\n* eGFR 45 to ≤90 mL\u002Fmin\u002F1.73 m2\n* UACR \\>200 mg\u002Fg\n* diagnosis of T2D\n* receiving ≤2 guideline-recommended drug classes irrespective of dose for ≥4 weeks prior to screening\n* eligible for all 4 drugs\n* systolic BP (SBP) \\>90 mmHg\n* those willing to provide written informed consent and to adhere to study visits.\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* any known primary non-diabetic kidney disease (i.e., polycystic kidney disease, glomerulonephritis, interstitial nephritis, etc.)\n* history of kidney transplant\n* liver disease (i.e., aspartate transaminase or alanine transaminase \\>5 times, or bilirubin \\>3 times the upper limit of normal)\n* serum potassium \\>5.5 mEq\u002FL at baseline\n* known hypersensitivity to any study drug\n* life expectancy \\\u003C6 months\n* active malignancy or infection\n* brittle diabetes (defined as severe glycemic instability with hospitalization or emergency care for hypoglycemia or hyperglycemia within the past 6 months)\n* high-risk of hypoglycemia (Clarke or Gold score ≥4)\n* predicted 12-month risk of hypoglycemia related emergency visits or hospitalizations \\>5% using the Kaiser Permanente hypoglycemia prediction score\n* high dose insulin use (\\>1 unit\u002Fkg\u002Fday).\n* RASi: hyperkalemia or angioedema\n* SGLT2i: diabetic ketoacidosis, type 1 diabetes, recurrent genitourinary infections\n* ns-MRA: hyperkalemia\n* GLP1-RA: personal or family history of medullary thyroid carcinoma, known gastroparesis, or pancreatitis.","84 Years",{"count":159,"type":22},64,[136],"The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease.\n\nThe main questions it aims to answer are:\n\n* Is it safe to start these medicines over a short period of time?\n* How often do kidney function changes or high potassium levels occur?\n* Does this approach lower protein in the urine (a sign of kidney damage)?\n* How many participants are able to stay on all four medicines over 6 months?\n\nResearchers will compare this approach to usual care, where medicines are started one at a time over several months.\n\nParticipants will:\n\nBe assigned by chance to either this approach or usual care Start up to four approved kidney medicines over about 8 weeks (rapid treatment approach) or follow standard care Have regular clinic visits and lab tests to check kidney function and potassium levels Be followed for about 6 months",[79,80],[79,80,164,85,90,165,166,167,83,168,169],"Rapid Therapy Initiation","Sodium-Glucose Cotransporter 2 Inhibitors","Non-steroidal Mineralocorticoid Receptor Antagonist","Glucagon-Like Peptide-1 Receptor Agonist","Estimated Glomerular Filtration Rate","Hyperkalemia","2026-05-07",{"date":63,"type":33},{"date":173,"type":22},"2026-04-30",{"date":175,"type":22},"2029-03-31",{"name":39,"class":40},{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":17,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":52,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":41},"100628357","proactive-athlete-heart-program-proposal-for-cardiac-risk-screening-in-former-high-intensity-athletes-100628357","NCT07460583","ProActive Athlete Heart Program: Proposal for Cardiac Risk Screening in Former High-Intensity Athletes","Inclusion Criteria:\n\n* Former professional or collegiate high-intensity athletes (e.g., NFL alumni, Division I athletes, or equivalent competitive-level participants).\n* Age ≥30 years\n\nExclusion Criteria:\n\n* eGFR \\\u003C40 mL\u002Fmin\u002F1.73 m²\n* Known iodinated contrast allergy\n* Weight \\>450 lbs. (scanner table limit)\n* Inability to hold breath \\>10 seconds\n* Uncontrolled arrhythmia\n* Contraindication to beta-blocker, Calcium Channel Blockers and nitroglycerin\n* Taking part in another research study that has not given their permission to participate in this one\n* Pregnancy","30 Years",{"count":185,"type":22},100,[54],"AI-Guided Coronary CT Angiography Screening in Former High-Intensity Athletes",[189],"Coronary Atherosclerosis Due to Calcified Coronary Lesion",{"date":191,"type":33},"2026-05-05",{"date":193,"type":22},"2026-08-28",{"date":195,"type":22},"2027-01-31",{"name":39,"class":40},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":52,"phases":205,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":41},"100585018","analysis-of-coronary-reactivity-testing-with-and-without-intracoronary-nitrate-testing-100585018","NCT06896903","Analysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing","CRT-NITRO","Inclusion Criteria:\n\n1. Aged 18 or older\n2. Patient being evaluated for ANOCA or INOCA\n3. Clinical suspicion for angina\n4. Patient should be able to comply with the protocol.\n5. Provide written informed consent before study participation.\n\nExclusion Criteria:\n\n1. Existing coronary artery disease\n2. Previous percutaneous interventions within the coronaries\n3. Current use (within 48 hours) of long-acting nitrate therapies\n4. Current use (within 48 hours) of PDE-5 inhibitors (sildenafil, tadalafil)\n5. Any other condition or co-morbidity which, in the opinion of the investigator or operator, may pose a significant hazard to the subject if he or she is enrolled in the study.\n6. Children below 18 years, prisoners, pregnant people and patients who are unable to provide consent are excluded.",{"count":114,"type":22},[54],"This single-arm, multi-center, prospective study will assess the coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and determinants thereof (transit time, Pa, Pd) in patients before and after intracoronary nitroglycerine.",[208,209],"ANOCA - Angina With Non-obstructive Coronary Arteries","INOCA (Ischemia With Non Obstructive Coronary Artery Disease)",[211,212],"Coronary Reactivity Testing","Intracoronary Nitroglycerine",{"date":191,"type":33},{"date":215,"type":33},"2025-05-21",{"date":217,"type":22},"2027-06-01",{"name":39,"class":40},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":226,"minAge":18,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":41},"100625390","tacrolimus-in-pregnancy-100625390","NCT07422012","Tacrolimus in Pregnancy","Optimization of Tacrolimus Management During Pregnancy: Modeling of Unbound and Whole Blood Tacrolimus in Pregnant Uterus Transplant Recipients","Inclusion Criteria:\n\n* Uterus transplant recipient\n* 18 to 50 years of age\n* receiving tacrolimus for immunosuppression.\n\nExclusion Criteria:\n\n* Individuals who have not had a uterine transplant\n* individuals over 50 years old","FEMALE","50 Years",{"count":229,"type":22},55,"To create a formula that adjusts tacrolimus blood levels. This is needed because pregnant patients have higher levels of unbound tacrolimus. The adjusted formula will give a more accurate measure of the active drug in pregnant uterus transplant patients.",[232,233],"Unbound Tacrolimus in Pregnant Uterus Transplant Recipients","Whole Blood Tacrolimus in Pregnant Uterus Transplant Recipients","2026-04-24",{"date":236,"type":33},"2026-04-28",{"date":238,"type":22},"2026-05-31",{"date":240,"type":22},"2028-03",{"name":39,"class":40},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":41},"100543192","prospective-long-term-outcomes-of-a-standardized-ross-procedure-100543192","NCT06352671","Prospective Long-Term Outcomes of a Standardized Ross Procedure","ROSS","Inclusion Criteria:\n\n* Patients undergoing Ross procedure at Baylor Scott and White The Heart Hospital, Plano, The University of Pennsylvania, The University of Washington, and Northwestern University.\n\nExclusion Criteria:\n\n* Less than 18 years of age\n* Presence of active malignancy\n* Pregnant at the time of surgery\n* Inability to provide informed consent","90 Years",{"count":251,"type":22},225,"This standardized prospective long-term outcome analysis will help reaffirm these findings via a multicenter patient cohort and describe the best practices\u002Ftechniques for stabilization of the autograft and right ventricular outflow tract reconstruction.",[254],"Aortic Valve Disease","2026-04-13",{"date":257,"type":33},"2026-04-15",{"date":259,"type":33},"2023-10-12",{"date":261,"type":22},"2026-12-01",{"name":39,"class":40},{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":249,"enrollmentInfo":270,"targetDuration":4,"studyType":52,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":41},"100542863","intracardiac-versus-transesophageal-echocardiographic-guidance-for-left-atrial-appendage-occlusion-100542863","NCT06348394","Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion","ICETEE","Inclusion Criteria:\n\n1. Patients diagnosed for non-valvular atrial fibrillation with documented paroxysmal, persistent, or permanent NVAF.\n2. Deemed to be at high risk of stroke or systemic embolism (SE) defined as a CHADS2 score ≥2 or a CHA2DS2-VASc score ≥3.\n3. Patient suitable for OAC with warfarin or DOAC and have appropriate rationale to seek a nonpharmacologic alternative to long-term OAC, meeting commercial LAAO criteria indications.\n4. Can undergo appropriate pre-procedural imaging with Computed tomography (CT) or transesophageal echocardiography (TEE).\n5. Patient should be able to comply with the protocol.\n6. Provide written informed consent before study participation.\n7. Ages 18 and above\n\nExclusion Criteria\n\n1\\) A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:\n\n1. Presence of an intracardiac thrombus on the preprocedural TEE or CT.\n2. History of previously implanted device for atrial septal defect or patent foramen ovale.\n3. Severe LV dysfunction (LVEF \\\u003C 40%) or greater than moderate valvular heart disease.\n4. Enrollment in another study that competes or interferes with this study. Approval to dual enroll must be approved by the other study.\n5. Poor clinical condition like cardiogenic shock, which prohibits pre- and post-procedural function tests.\n6. Subject with planned cardiac intervention between the time of consenting and up to 60 days post-LAAO.\n7. Any other condition or co-morbidity which, in the opinion of the investigator or operator, may pose a significant hazard to the subject if he or she is enrolled in the study.\n8. For women of childbearing potential: Pregnant or breastfeeding women or planning pregnancy during the course of the investigation are excluded due to the risks involved in the procedure\n9. Children below 18 years, prisoners and patients who are unable to provide consent are excluded.",{"count":271,"type":22},444,[54],"This single-center, prospective, randomized study will evaluate the safety and feasibility of Intracardiac echocardiography (ICE)-guided Left atrial appendage closure (LAAC) when compared to the traditional Transesophageal echocardiography (TEE) approach.",[275],"Left Atrial Appendage Closure",{"date":257,"type":33},{"date":278,"type":33},"2025-02-25",{"date":280,"type":22},"2026-12-30",{"name":39,"class":40},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":52,"phases":291,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":308},"100620152","intravascular-ultrasound-imaging-guidance-for-optimal-revascularization-of-limb-arteries-100620152","NCT07353905","Intravascular Ultrasound Imaging Guidance for Optimal Revascularization of Limb Arteries","INVIGOR","Inclusion Criteria:\n\n* Age ≥18 years\n* Symptomatic LE PAD - Rutherford Class 2-5\n* Angiographic evidence of \\>50% stenosis\n* Undergoing LE peripheral artery intervention\n* Target lesion is iliac, femoropopliteal, profunda or supramalleolar below-the-knee arteries (target lesions extending into the abdominal aorta and inframalleolar BTK may be included).\n\nExclusion Criteria:\n\n* Prior intervention at the target lesion within 6 months\n* Target lesion is abdominal aorta or inframalleolar BTK arteries",{"count":290,"type":22},350,[54],"This study will test whether using ultrasound imaging within blood vessels during minimally invasive treatment of leg arteries in patients with peripheral artery disease leads to better clinical outcomes.",[294,295],"Peripheral Arterial Disease","Lower Extremity Arterial Disease",[297,298,299],"Intravascular Ultrasound","Angioplasty","Endovascular Treatment","2026-03-17",{"date":302,"type":33},"2026-03-19",{"date":304,"type":33},"2025-12-12",{"date":306,"type":22},"2028-07",{"name":39,"class":40},6,{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":52,"phases":319,"briefSummary":314,"conditions":320,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":41},"100628905","study-to-evaluate-the-clinical-utility-of-radiation-exposure-reduction-multi-site-rampart-guardian-peripheral-trial-100628905","NCT07467720","Study to Evaluate the Clinical Utility of Radiation Exposure Reduction: Multi-site Rampart Guardian Peripheral Trial","Study to Evaluate the Clinical Utility of Radiation Exposure Reduction (SECURE): Multi-site Rampart Guardian Peripheral Trial","SECURE","Inclusion Criteria:\n\n* Member of the interventional care team\n* Elective peripheral procedure\n* The access site is the femoral artery\n* The treatment area is at or distal to the iliac artery\n\nExclusion Criteria:\n\n* Individuals who are not yet adults, pregnant women, or prisoners.\n* Urgent and emergent cases",{"count":318,"type":22},75,[54],[321],"Radiation Protection","2026-03-16",{"date":324,"type":33},"2026-03-18",{"date":326,"type":22},"2026-05-15",{"date":328,"type":22},"2027-05-15",{"name":39,"class":40},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":340,"studyType":23,"phases":4,"briefSummary":341,"conditions":342,"keywords":344,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":356},"100467821","the-tiob---collection-of-patients-biospecimens-for-analysis-of-immunological-and-molecular-biomarkers-100467821","NCT05371756","The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.","The Texas Immuno-Oncology Biorepository: Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers That Predict Benefit\u002FResistance to Cancer Therapeutics.","TIOB","Inclusion Criteria:\n\n* Participant is over 18 years of age at the time of signing the informed consent form.\n* Participant is able and willing to sign an informed consent form.\n* Participant is suspected by a provider of being at risk for developing cancer,\n\nOR\n\n* Participant has confirmed or clinically suspected malignancy by a provider. This includes but is not limited to:\n\n  1. Participants who may be candidates for or are scheduled to receive standard of care immunotherapy treatment for the first time for their current cancer diagnosis, regardless of any prior non-immunotherapy treatment.\n  2. Participants who are enrolled in a clinical trial to receive an investigational, novel immunotherapy drug for the first time for their current cancer diagnosis.\n  3. Participants who may be surgical candidates for their current cancer diagnosis, regardless of any prior treatment.\n\nExclusion Criteria:\n\n* Participant is unable or unwilling to donate blood.\n* Concurrent medical or psychiatric condition or disease that may compromise the ability to give documented informed consent, is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.",{"count":339,"type":22},10000,"5 Years","The purpose of the Texas Immuno-Oncology Biorepository (TIOB) is to collect and store well-defined and well-annotated serial biospecimens of tissue, blood, urine and stool in a longitudinal manner from cancer patients who are receiving either standard of care surgical interventions and or FDA approved immunotherapeutics across the largest not-for-profit health system in Texas. Comprehensive clinical and radiological data from a diverse population of patients with different racial, social and ethnic backgrounds matched with serial biospecimens over a patients journey with cancer marks the TIOB as a unique research facility.",[343],"Cancer",[345,346,347,348],"Biorepository","Immuno-Oncology","Molecular Biomarkers","Benefit & Resistance","2026-03-12",{"date":322,"type":33},{"date":352,"type":33},"2020-09-11",{"date":354,"type":22},"2050-09-11",{"name":39,"class":40},8,{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":52,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":41},"100625579","foregut-leaks-role-of-microbiome-100625579","NCT07424469","Foregut Leaks-Role of Microbiome","The Role the Microbiome Plays in Foregut Leaks: Understanding and Utilizing This Information to Improve Patient Outcomes","Inclusion Criteria:\n\n* Patients with an esophageal or stomach leak\n* Over 18 years old\n\nExclusion Criteria:\n\n* Patients determined by physician\u002Fsurgeon as not able to tolerate biopsy\n* Under 18 years old",{"count":114,"type":22},[54],"Aims\n\n1. To understand the microbial composition involved with foregut leaks\n2. To define the virulence changes in the microbiota following foregut leaks\n3. To identify host response mechanisms and how they change with interventions\n4. Utilize this information to improve patient outcomes",[368],"Gastrointestinal Diseases","2026-02-13",{"date":371,"type":33},"2026-02-20",{"date":373,"type":33},"2020-08-14",{"date":375,"type":22},"2028-06-01",{"name":39,"class":40},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":384,"sex":17,"minAge":385,"maxAge":157,"enrollmentInfo":386,"targetDuration":4,"studyType":52,"phases":388,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":403,"leadSponsor":405,"locationsCount":41},"100623578","smartphone-enabled-hybrid-identification-of-early-colorectal-disease-using-blood-based-cancer-testing-across-texas-100623578","NCT07398456","Smartphone-enabled Hybrid Identification of Early CoLorectal Disease Using Blood-Based Cancer Testing Across TeXas","SHIELD-TX","Inclusion Criteria:\n\n* patients aged 45-84 years of age\n* Considered by health-care providers to be \"average risk\" for CRC as determined by USPSTF guidelines\n* If a patient opts for BBST, they are able and willing to provide blood samples per protocol\n* Ability to understand and the willingness to participate in the study\n* Must have been seen in HTPN clinic within the past 24 months from study activation\n* Must have active MyBSW app portal account and\u002For establish account during study recruitment\n\nExclusion Criteria:\n\n* Patients with a personal history of CRC\n* Patients with a known high-risk family history of CRC precluding the patient from being average risk\n* Patients with known diagnosis of inflammatory bowel disease or history of polyps\n* Patients who are currently symptomatic for CRC such as: blood in the stool\n* Patients with any known medical condition which, in the opinion of the investigator, should preclude enrollment into the study\n* Have a recorded up to date CRC screening in the EMR (within 1 year for FIT, 3 years for mt-sDNA, 10 years for colonoscopy)\n* Patients with a previous abnormal colonoscopy finding who are due for surveillance.",true,"45 Years",{"count":387,"type":22},5500,[54],"The goal of this prospective implementation study is to understand the impact of a blood-based screening test (BBST) for colorectal cancer (CRC) on patient acceptability of and adherence to CRC screening as well as the rate of follow-up BBST in those with negative BBST at a 1-year interval.\n\nAdditional aims include assessing the impact of digital patient navigation intervention on the rate of follow-up colonoscopy in individuals with positive BBST. Patients will be randomized into the non-intervention arm or the intervention with an app arm.",[391],"Colorectal Cancer (CRC) Screening",[393,394,395,396,397,398],"blood-based screening test","cancer risk","colorectal cancer risk","circulating tumor DNA","cell-free DNA","colorectal cancer screening","2026-02-10",{"date":401,"type":33},"2026-02-12",{"date":146,"type":22},{"date":404,"type":22},"2028-06",{"name":39,"class":40},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":52,"phases":416,"briefSummary":418,"conditions":419,"keywords":423,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":41},"100555832","phase-2-tirzepatide-weight-loss-for-mrd-early-breast-cancer-100555832","NCT06517212","Tirzepatide Weight Loss for MRD+ Early Breast Cancer","Adjuvant Tirzepatide Plus Standard of Care Endocrine Therapy in Patients With Obesity or Overweight Who Have Hormone Receptor-positive, HER2-negative, Node-positive Early Breast Cancer, With Molecular Residual Disease (MRD), as Determined by Circulating Tumor DNA (ctDNA)","TRIM-EBC","Inclusion Criteria:\n\n1. Female or male patients ≥18 years of age\n2. Have a diagnosis of node-positive, hormone receptor-positive (ER+ \\> 10%), and HER2-negative breast cancer within the past 15 years per the American Society of Clinical Oncology (ASCO)\u002FCollege of American Pathologists (CAP) guidelines\n\n   1. If patients have synchronous bilateral ER+ breast cancers, tissue from both primary cancers should be submitted for next-generation sequencing (NGS) to inform ctDNA testing\n   2. Patients with multifocal\u002Fmulticentric cancers are eligible and the largest focus of cancer should be submitted for NGS evaluation. If tested, all tumor foci must meet have ER \\> 10%\n   3. For patients who received neoadjuvant therapy and have discordant hormone receptor and\u002For HER2 results between the diagnostic biopsy (pre-treatment) and the surgical pathology (post-neoadjuvant treatment), the hormone receptor status and HER2 status of the post-treatment specimen will determine eligibility\n3. Overweight or obesity defined as body mass index (BMI) \\> 27 kg\u002Fm2\n4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n5. Have received at least 1 year of or having completed standard neo\u002Fadjuvant endocrine therapy. If adjuvant cyclin dependent kinase (CDK) 4\u002F6 inhibitor therapy was prescribed, patients must have completed this therapy\n6. Positive ctDNA blood test as determined by the Haystack Oncology Haystack MRD tumor-informed ctDNA assay\n7. Patients must have formalin-fixed paraffin-embedded (FFPE) tissue from the primary tumor available for submission to Haystack Oncology to perform whole genome sequencing (WGS) to build customized mutation panel to monitor for plasma ctDNA\n8. No clinical evidence of metastatic breast cancer found on history, physical examination, complete blood count (CBC), comprehensive metabolic panel (CMP), and radiologic imaging following a finding of positive ctDNA\n9. Have adequate hematologic function, defined by:\n\n   1. Absolute neutrophil count (ANC) \\>1500\u002FµL\n   2. Platelet count ≥100,000\u002F µL\n   3. Hemoglobin ≥9 g\u002FdL or ≥5.6 mmol\u002FL\n10. Have adequate liver function, defined by:\n\n    1. Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤3 x the upper limit of normal (ULN)\n    2. Total bilirubin ≤1.5 x ULN OR direct bilirubin ≤ULN for patients with total bilirubin levels \\>1.5 × ULN\n11. Have adequate renal function, defined by:\n\n    a. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance of ≥30 mL\u002Fmin\n12. Patients must be accessible for treatment and follow-up\n13. All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry\n\nExclusion Criteria:\n\n1. Prior bariatric surgery and\u002For endoscopic procedures for weight loss (e.g., intragastric balloon, sleeve gastrostomy) following diagnosis of breast cancer\n2. Treatment with a GLP-1\u002FGlucagon receptor agonist, GIP\u002FGLP-1\u002FGlucagon receptor agonist, GIP\u002FGLP receptor agonist, or any combinations with GLP-1 receptor agonist therapies within the last 3 months\n3. History of severe hypersensitivity reaction to GLP-1\u002FGlucagon receptor agonist, GIP\u002FGLP-1\u002FGlucagon receptor agonist, or any combinations with GLP-1 receptor agonist therapies\n4. Insulin-dependent diabetes\n5. Has clinical evidence of diabetic retinopathy\n6. Clinical evidence or suspicion of metastatic breast cancer\n7. Current or past invasive cancers, other than breast cancer, are not allowed except for:\n\n   1. Adequately treated basal or squamous cell carcinoma of the skin\n   2. Previously diagnosed invasive cancer treated with curative intent, with no evidence of disease recurrence for at least 5 years, and are considered low risk for future recurrence by the treating physician\n8. Patients with a second synchronous primary HER2-positive or triple negative breast cancer\n9. Has an active infection requiring systemic therapy\n10. Has a known history of human immunodeficiency virus (HIV) or active or persistent hepatitis B or hepatitis C virus\n11. Has significant cardiovascular disease, such as:\n\n    1. History of stroke, myocardial infarction, acute coronary syndrome, or coronary angioplasty\u002Fstenting\u002Fbypass grafting within the last 6 months\n    2. Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV, or history of CHF NYHA class III or IV.\n12. Has a known history of active tuberculosis\n13. Women who are pregnant or lactating. All patients of reproductive potential must agree to use effective contraception from time of study entry until at least 3 months after the last administration of study drug\n14. Patients who have any severe and\u002For uncontrolled medical conditions or other conditions that could affect their participation such as:\n\n    1. severe impaired lung functions as defined as spirometry and diffusing capacity of lung for carbon monoxide (DLCO) that is 50% of the normal predicted value and\u002For O2 saturation that is 88% or less at rest on room air\n    2. liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C)\n    3. history of gastroparesis, impaired gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of the study drug (e.g., ulcerative diseases, uncontrolled nausea vomiting and\u002For diarrhea, malabsorption syndrome, or small bowel resection)\n15. Has a history of pancreatitis or current symptoms of untreated cholelithiasis\n16. Has a family history of Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2) or medullary thyroid cancer (MTC)\n17. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's full participation for the full duration of the study, or results in trial participation not being in the patient's best interest, in the opinion of the Treating Physician\n18. Has received an investigational agent within 4 weeks prior to study treatment; investigational monoclonal antibodies should have a 4-week (28 day) or 5 half-life washout period\n19. Any other investigational or anti-cancer treatments while participating in this study with the exception of standard adjuvant endocrine therapy, zoledronic acid, or denosumab",{"count":415,"type":22},48,[417],"PHASE2","This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.",[420,421,422],"Breast Cancer","Breast Neoplasms","Breast Cancers",[424,425,412,426,427,428],"TRIM","TRIM EBC","tirzepatide","MRD","ctDNA",{"date":401,"type":33},{"date":431,"type":33},"2024-11-26",{"date":433,"type":22},"2030-12-31",{"name":39,"class":40},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":226,"minAge":18,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":52,"phases":444,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":41},"100382918","early-phase-1-bortezomib-followed-by-pembrolizumab-and-cisplatin-in-mettnbc-100382918","NCT04265872","Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC","Pilot Clinical Trial of Treatment With Bortezomib to Inhibit Homologous Recombination (HR) Followed by Pembrolizumab and Cisplatin in Patients With Chemotherapy-Pretreated Metastatic Triple Negative Breast Cancer","Inclusion Criteria:\n\n* A patient will be eligible for inclusion in this study if she meets all of the following criteria:\n\n  1. Female patients ≥18 years of age\n  2. Have a diagnosis of metastatic TNBC previously treated with standard anthracycline, cyclophosphamide, and taxane chemotherapy, unless there was a contraindication to doxorubicin, in which case prior treatment with this agent is not required. NOTE: TNBC defined as ER-negative tumors with \\\u003C or = 10% tumor nuclei immunoreactivity, or \"ER Low Positive\" as defined by the updated ASCO\u002FCAP guidelines 2020.\n  3. Have not received more than 3 prior chemotherapy regimens for metastatic disease. Prior platinum and\u002For taxane therapy in the adjuvant or metastatic setting is permitted.\n  4. Have locoregional (eg, breast, chest wall, regional lymphatic) or pulmonary or hepatic metastatic disease that is amenable to core needle biopsy. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted. If a skin biopsy cannot be safely obtained, patients may still be eligible, per physician discretion.\n  5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (See Appendix I)\n  6. Have adequate hematologic function, defined by:\n\n     1. Absolute neutrophil count (ANC) \\>1500\u002FμL\n     2. Platelet count ≥100,000\u002FμL\n     3. Hemoglobin ≥9 g\u002FdL or ≥5.6 mmol\u002FL\n  7. Have adequate liver function, defined by:\n\n     1. AST and ALT ≤2.5 x the upper limit of normal (ULN) or ≤5 x ULN in presence of liver metastases\n     2. Total bilirubin ≤1.5 x ULN OR direct bilirubin ≤ULN for patients with total bilirubin levels \\>1.5 × ULN\n  8. Have adequate renal function, defined by:\n\n     a. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance of ≥30 mL\u002Fmin\n  9. Have adequate coagulation function, defined by:\n\n     1. International Normalized Ratio (INR) OR prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN.\n     2. If patient is receiving anticoagulant therapy, PT or aPTT must be within therapeutic range of intended use of anticoagulants.\n  10. Patients who have a history of brain metastasis are eligible for the study provided that all the following criteria are met:\n\n      1. Brain metastases which have been treated\n      2. Off-treatment with steroids for 2 weeks before administration of the first dose of bortezomib\n      3. No ongoing requirement for dexamethasone or anti-epileptic drugs\n      4. No clinical or radiological evidence of progression of brain metastases\n  11. Patient must be accessible for treatment and follow-up.\n  12. All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry.\n\nExclusion Criteria:\n\n* EXCLUSION CRITERIA\n\nA patient will be ineligible for inclusion in this study if she meets any of the following criteria:\n\n1. Has received a live vaccine within 30 days of the first dose of study treatment. NOTE: seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (ie, FluMist ®) are live attenuated vaccines, and are not allowed.\n2. Has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic therapy.\n3. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n4. Has a known history of Human Immunodeficiency Virus (HIV)\n5. Has known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection\n6. Has a history of non-infectious pneumonitis that required steroids or current pneumonitis\n7. Has peripheral neuropathy ≥grade 2\n8. Has completed previous radiotherapy for metastatic disease \\\u003C2 weeks prior to study treatment initiation\n9. Has an active infection requiring systemic therapy\n10. Has significant cardiovascular disease, such as:\n\n    1. History of myocardial infarction, acute coronary syndrome, or coronary angioplasty\u002Fstenting\u002Fbypass grafting within the last 6 months\n    2. Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV, or history of CHF NYHA class III or IV.\n11. Has a known history of active tuberculosis\n12. Women who are pregnant or lactating. All patients with reproductive potential must agree to use effective contraception from time of study entry until at least 3 months after the last administration of study drug.\n13. Patients who have any severe and\u002For uncontrolled medical conditions or other conditions that could affect their participation such as:\n\n    1. severe impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and\u002For O2 saturation that is 88% or less at rest on room air\n    2. liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C).\n14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the Treating Physician.\n15. Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study treatment (this would not include bortezomib while on study). Monoclonal antibody agents should have a 4-week (28 day) washout period.\n16. Any other investigational or anti-cancer treatments while participating in this study\n17. Any other active malignancy",{"count":443,"type":22},20,[445],"EARLY_PHASE1","The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in depth analysis of the patients' TNBC genome and phosphoproteome to evaluate HR-proficiency and deficiency, and nuclear proteins that drive NHEJ, before and upon progression with bortezomib therapy.",[420],{"date":401,"type":33},{"date":450,"type":33},"2020-10-15",{"date":452,"type":22},"2027-03-31",{"name":39,"class":40},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":461,"enrollmentInfo":462,"targetDuration":4,"studyType":52,"phases":464,"briefSummary":465,"conditions":466,"keywords":470,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":481},"100532277","trauma-bpe-prolonged-exposure-therapy-for-injured-individuals-admitted-to-a-level-i-trauma-center-100532277","NCT06210711","Trauma BPE Prolonged Exposure Therapy for Injured Individuals Admitted to a Level I Trauma Center","Prevention of Posttraumatic Stress: A Randomized Controlled Trial of Brief Prolonged Exposure Therapy for Injured Individuals Admitted to a Level I Trauma Center","Inclusion Criteria:\n\n* Between the ages of 18 and 75 years old.\n* Admitted to Baylor University Medical Center at Dallas (BUMC), Baylor Scott \\& White Medical Center at Temple (BSWMC), or Froedtert Hospital and the Medical College of Wisconsin (FH\u002FMCW) Level 1 Trauma Center\n\nExclusion Criteria:\n\n* Patients in police custody\n* Patients not fluent in English\n* Patients with severe cognitive impairment\n* Patients who are acutely suicidal\n* Patients with active psychosis","75 Years",{"count":463,"type":22},300,[54],"The purpose of this research is to determine if a brief treatment method is effective for preventing posttraumatic stress disorder (PTSD) and a number of other concerns following injury.",[467,468,469],"Traumatic Injury","PTSD","Posttraumatic Stress Disorder",[468,471,472],"Traumatic injury","Posttraumatic stress disorder","2026-02-09",{"date":475,"type":33},"2026-02-11",{"date":477,"type":33},"2024-02-28",{"date":479,"type":22},"2027-09",{"name":39,"class":40},3,{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":489,"targetDuration":4,"studyType":52,"phases":491,"briefSummary":492,"conditions":493,"keywords":495,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":41},"100549178","early-robotic-gait-training-after-stroke-100549178","NCT06430632","Early Robotic Gait Training After Stroke","ERA Stroke","Inclusion Criteria:\n\n* 18-85 years of age\n* All types of stroke\n* Acute\u002Fsubacute phase of recovery\n* Medically stable as deemed by a physician\n* Undergoing medical care and rehabilitation at BSWIR\n* All genders, races, and ethnicities\n* Meets Ekso robotic exoskeleton frame limitations\n* Continence or on a program for bladder and bowel management\n* Capacity and goal for walking recovery\n\nExclusion Criteria:\n\n* Concurrent neurological diagnoses (e.g., TBI, degenerative, CNS neoplasm)\n* Profound cognitive impairment\n* Pregnancy",{"count":490,"type":22},54,[54],"The ERA Stroke project will compare the effects of robotic gait training (RGT) and usual care (UC) gait training in patients in the subacute phase of stroke recovery undergoing inpatient rehabilitation at the Baylor Scott \\& White Institute for Rehabilitation (BSWIR).",[494],"Stroke",[496,497,498,499,500,501,502],"Exoskeleton","Gait training","Inpatient rehabilitation","Physical therapy","Physical rehabilitation and medicine","Randomized controlled trial","Robotic gait training","2026-02-04",{"date":505,"type":33},"2026-02-06",{"date":507,"type":33},"2024-03-01",{"date":509,"type":22},"2026-12",{"name":39,"class":40},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":519,"targetDuration":521,"studyType":23,"phases":4,"briefSummary":522,"conditions":523,"keywords":524,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":534},"100201911","multi-center-registry-for-peripheral-arterial-disease-interventions-and-outcomes-100201911","NCT01904851","Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes","Multi-Center Registry Comparing Stent and Non-Stent Based Interventional Outcomes for Patients With Peripheral Arterial Disease","XLPAD","Inclusion Criteria:\n\n* Underwent Endovascular Intervention\n* Treated Iliac, Common or Superficial Femoral, Popliteal, Peroneal, Anterior Tibial, or Posterior Tibial Arteries\n\nExclusion Criteria:\n\n* Surgical Bypass",{"count":520,"type":22},14000,"12 Months","XLPAD is an observational study designed to evaluate the effectiveness and use of stent and non-stent based therapies among PAD patients. The study will create a registry that will include entry of procedural and clinical follow-up information into an online data collection software, REDCAP.Data available since Jan 1 2005 will be included in the registry, until 14,000 patients have been included. The primary objectives of this observational registry study are to:\n\n1. Compare stent and non-stent based outcomes defined as a composite of symptom driven target vessel revascularization (TVR), unplanned surgical revascularization of the target limb and need for target limb amputation through 12 months post-index procedure (Primary efficacy endpoint)\n2. Compare stent and non-stent based outcomes defined as a composite of causes such as: death, myocardial infarction (MI), stroke, peri-procedural complications, target vessel revascularization (TVR) and unplanned surgical revascularization\u002Famputation of the target limb through 12 months (Primary safety endpoint)\n3. Compare stent and non-stent based change in walking distance, Rutherford category and\u002For ankle- brachial index (ABI) at 12 months compared to baseline (Primary clinical improvement endpoint)\n\nApproximately 14,000patients will be enrolled at approximately 60 sites worldwide. Enrollment in the observational study will be monitored in an effort to achieve at least 20% (and no more than 80%) of the population receiving stents as the initial treatment strategy. Follow-up visits by sites will be reported at 6 and 12 months after index procedure to collect data on treatment patterns and effectiveness, and outcomes. The follow-up procedures are not mandated by the registry protocol. Each site will be encouraged to enter follow-up information derived from clinically indicated follow-up visits. All events post-index procedure till the 7th month will be reported under the 6 month follow-up form and subsequent follow-up till the 13th month post-procedure will be entered on the 12 month follow-up form.\n\nPatient management and treatment decisions are at the discretion of the care team per routine clinical practice. The procedural aspects (including selection of stent type or non-stent based treatments) and follow-up are not mandated by the registry and will be up to the discretion of the operator and\u002For based upon the practice dictated by the clinical care of the patient. Therefore the study poses minimal risk to the patient.",[294],[294,525,526,298,527],"Stents","Registry","Endovascular Procedures",{"date":505,"type":33},{"date":530,"type":4},"2013-01",{"date":532,"type":22},"2033-01",{"name":39,"class":40},24,{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":52,"phases":544,"briefSummary":545,"conditions":546,"keywords":548,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":41},"100620151","robotic-exoskeletons-in-acute-care-therapy-100620151","NCT07353892","Robotic Exoskeletons in Acute Care Therapy","Robotic Exoskeletons in Acute Care Therapy - Cardiovascular and Thoracic Surgery","REACT-CVTS","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Underwent cardiovascular or thoracic surgery, including but not limited to coronary artery bypass grafting, valve replacement\u002Frepair, lung resection, or advanced cardiovascular or pulmonary therapies \\[transplant, durable or temporary ventricular assist device implantation (VAD), temporary mechanical circulatory support (tMCS), venovenous extracorporeal membrane oxygenation (VV ECMO)\\].\n3. Medically appropriate for physical therapy, including upright activity and ambulation, as defined by an order in the patient's electronic medical record signed by a physician or advanced practice provider.\n4. Requires ≥ 50% assist to perform upright activity based on physical therapy assessments (e.g., AMPAC-6 clicks or JH-HLM)\n5. English or Spanish-speaking\n6. Able to provide written informed consent (or via a legally authorized representative if applicable)\n7. Meets ORE frame limitations (height = 5'2\" to 6'4\" and weight ≤ 220 lbs.)\n\nExclusion Criteria:\n\n1. Cognitive or behavioral impairment that interferes with safe participation \\[e.g., active delirium (positive CAM-ICU score) or unable to follow commands\\].\n2. Moderate vasopressor or inotrope requirements, including:\n\n   \\>0.10 mcg\u002Fkg\u002Fmin of norepinephrine \\>0.03 mcg\u002Fkg\u002Fmin of epinephrine \\>80.0 mcg\u002Fkg\u002Fmin of phenylephrine \\>0.04 units\u002Fmin of vasopressin \\>5.0 mcg\u002Fkg\u002Fmin of dobutamine \\>5.0 mcg\u002Fkg\u002Fmin dopamine \\>0.50 mcg\u002Fkg\u002Fmin of milrinone Any combination of \\> 3 of any of these, regardless of dose, unless deemed acceptable at the discretion of the treating attending.\n3. Sustained ventricular arrhythmias that require intervention at the time of upright mobilization.\n4. Any active dose of angiotensin II\n5. Positive end-expiratory pressure (PEEP) ≥ 10 cm H20).\n6. Except for those with a femoral arterial balloon pump, all patients with existing femoral arterial lines at the time of ambulation are ineligible. However, patients with femoral intraortic balloon pump (IABP) may be considered if, in the judgment of the attending physician and physical therapy team, patient is appropriate for ambulation given patient's clinical status and IABP site and securement status, and if ambulation of appropriate patients with femoral IABP is consistent with local standard of care at the time of ambulation.\n7. Skin disintegrity in proximity to the ORE frame\n8. Participation in another interventional study that may confound outcome measures.\n9. Pregnancy\n10. Any other condition that, in the judgment of the clinical or research team, would pose an unacceptable risk or interfere with study participation or interpretation.",{"count":443,"type":22},[54],"The goal of this clinical trial is to establish the safety, feasibility, and preliminary findings of overground robotic exoskeleton early ambulation (ORE-EA) compared to usual care early ambulation (UC-EA) in the rehabilitation of patients who have had cardiovascular or thoracic surgery. The main questions it aims to answer are:\n\n* Is there a difference between groups in time between surgery and ambulation?\n* Are there differences in safety and feasibility?",[547],"Patients Post-cardiothoracic Surgery",[549,550,551],"cardiothoracic surgery","rehabilitation","ambulation","2026-01-28",{"date":554,"type":33},"2026-01-30",{"date":556,"type":33},"2025-12-02",{"date":558,"type":22},"2027-07-01",{"name":39,"class":40},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":568,"conditions":569,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":577,"locationsCount":41},"100413484","bio-banking-of-specimens-for-advanced-lung-disease-and-lung-transplant-research-100413484","NCT04664192","Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research","ALD Biobank","Inclusion Criteria:\n\n1. All individuals aged 18 years and older\n2. Persons who have undergone lung transplantation at Baylor University Medical Center in the previous 10 years\n3. Individual is able to understand and sign the informed consent form\n\nExclusion Criteria:\n\n1. Significant documented anemia (hemoglobin \\\u003C8 g\u002FdL)\n2. Blood transfusions within past 3 weeks\n3. Active cancer (non-skin cancers)\n4. Enrollment against doctor recommendation\n5. Patient not able to provide informed consent",{"count":185,"type":22},"A major goal of this protocol is to support biomarker studies in advanced lung diseases, lung transplantation care, and to improve our understanding of the effects of viral and other infectious exposures to outcomes in our lung transplant and ALD patient populations.",[570,571,572],"Respiratory Failure","Interstitial Lung Disease","Lung Diseases",{"date":554,"type":33},{"date":575,"type":33},"2021-06-04",{"date":261,"type":22},{"name":39,"class":40},{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":586,"enrollmentInfo":587,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":589,"conditions":590,"keywords":592,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":600,"locationsCount":41},"100420185","colon-md-colon-cancer-longitudinal-study-100420185","NCT04751448","COLON-MD: Colon Cancer Longitudinal Study","COLON MD: Colon Cancer Longitudinal Study of the Microbial Metabolites and Dietary Factors That Influence Response to Treatment","COLON-MD","Inclusion Criteria:\n\n* Colon cancer diagnosis\n* Age \\>18 and \\\u003C or equal to 79.\n* Ability to perform informed consent\n* FOLFOX treatment expected\n\nExclusion Criteria:\n\n* Not Pregnant\n* Does not have Lynch syndrome or FAP diagnosis.\n* Inability to perform inform consent\n* inability to comply with follow up program\n* history of prior colon cancer diagnosis\n* previous treatment with antibiotics in the last month.\n* previous bowel resection.","79 Years",{"count":588,"type":22},11,"The goal of this proposal is to identify how the composition of the gut microbiome and diet interact to impact chemotherapy-induced diarrhea incidence and severity.",[591],"Colon Cancer",[593],"FOLFOX Treatment","2026-01-23",{"date":596,"type":33},"2026-01-26",{"date":598,"type":33},"2021-02-01",{"date":59,"type":22},{"name":39,"class":40},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":249,"enrollmentInfo":608,"targetDuration":4,"studyType":52,"phases":610,"briefSummary":611,"conditions":612,"keywords":613,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":621,"locationsCount":481},"100315199","phase-2-transplant-of-redeemed-organs-by-judicious-administration-of-new-direct-acting-antivirals-for-hepatitis-c-heart-recipients-100315199","NCT03383419","Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients","TROJAN-C","Inclusion Criteria:\n\n1. Willing and capable of providing written informed consent\n2. Age ≥ 18 years\n3. Listed for isolated orthotopic heart transplant\n4. HCV seronegative (or, if HCV seropositive, then subject must be PCR negative on at least 2 draws consistent with a spontaneously cleared or fully-treated and cleared prior infection; in this case last anti-HCV antiviral dose must be ≥12 weeks ago and 2 negative titers ≥12 weeks after completion of the antiviral regimen)\n\nExclusion Criteria:\n\n1. Listed for combined organ transplant\n2. Any of the following liver disease states, including:\n\n   1. History of HCV viremia detectable by either HCV qualitative or quantitative PCR unless deemed cured (SVR-12),\n   2. Hepatitis B surface Ag positive(unless clinically determined to be previously negative and acutely positive due to vaccination with recombinant surface antigen) or detectable hepatitis B DNA,\n   3. Cirrhosis, as indicated by liver biopsy,\n   4. Portal hypertension as indicated by a hepatic venous pressure gradient \\> 5 mm Hg and\u002For the presence of esophageal varices e.) ALT and AST \\> 3x ULN unless adjudicated to be from a non-hepatic cardiac or skeletal muscle source,\n3. History of prior solid organ transplant\n4. Pregnant individuals\n5. History of HIV infection\n6. History of severe renal disease currently requiring dialysis. Chronic kidney disease with creatinine clearance \\\u003C30 ml\u002Fmin\u002F1.73m2 (by MDRD method) at screening or on last two consecutive measurements before acceptance of transplant organ offer\n7. Patients who have undergone or who will undergo immune desensitization therapy\n8. Prospective-positive cross-match or predicted positive cross-match\n9. Patients unwilling to notify their sexual partner(s) of participation in this trial",{"count":609,"type":22},15,[417],"This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg \u002F velpatasvir 100 mg (Epclusa®).",[57],[614],"Heart Failure, Heart Transplant","2026-01-21",{"date":617,"type":33},"2026-01-22",{"date":619,"type":33},"2018-03-20",{"date":280,"type":22},{"name":39,"class":40},""]